Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Authors
Keywords
-
Journal
CA-A CANCER JOURNAL FOR CLINICIANS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-05-17
DOI
10.3322/caac.21559
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Editorial
- (2018) C Fotopoulou et al. ANNALS OF ONCOLOGY
- Antibody–Drug Conjugates for Cancer Treatment
- (2018) John M. Lambert et al. Annual Review of Medicine
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores
- (2018) KE Broekman et al. CANCER TREATMENT REVIEWS
- Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
- (2018) Allen W. Zhang et al. CELL
- Perineal Talc Use and Ovarian Cancer
- (2018) Ross Penninkilampi et al. EPIDEMIOLOGY
- FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
- (2018) Kathleen N Moore et al. Future Oncology
- A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer
- (2018) Kathleen N Moore et al. Future Oncology
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium
- (2018) Britton Trabert et al. JNCI-Journal of the National Cancer Institute
- Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
- (2018) Lauren C Peres et al. JNCI-Journal of the National Cancer Institute
- Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
- (2018) Amit M Oza et al. LANCET ONCOLOGY
- Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
- (2018) Michael Friedlander et al. LANCET ONCOLOGY
- Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study
- (2018) Melissa A Merritt et al. LANCET ONCOLOGY
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
- (2018) Willemien J. van Driel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Personalized vaccines for cancer immunotherapy
- (2018) Ugur Sahin et al. SCIENCE
- Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium
- (2018) Britton Trabert et al. JNCI-Journal of the National Cancer Institute
- Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
- (2018) Lauren C Peres et al. JNCI-Journal of the National Cancer Institute
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
- (2018) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.
- (2018) Robert Allen Burger et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.
- (2018) Robert L. Coleman et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical data from the DeCidE1 trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer.
- (2018) Oliver Dorigo et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.
- (2018) Sandro Pignata et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.
- (2018) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Copy number signatures and mutational processes in ovarian carcinoma
- (2018) Geoff Macintyre et al. NATURE GENETICS
- Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer
- (2018) Nicole D. Fleming et al. OBSTETRICS AND GYNECOLOGY
- The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
- (2018) Tyvette Hilliard Cancers
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing
- (2017) Yusuke Shibuya et al. GENES CHROMOSOMES & CANCER
- Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer
- (2017) Amit M. Oza et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study
- (2017) Adam N. Rosenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
- (2017) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference
- (2017) Ji Yon Agnes Jang et al. Journal of Gynecologic Oncology
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- High grade serous ovarian carcinomas originate in the fallopian tube
- (2017) S. Intidhar Labidi-Galy et al. Nature Communications
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)
- (2017) Zheng Feng et al. Journal of Ovarian Research
- The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer
- (2017) Martin Widschwendter et al. Genome Medicine
- Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression
- (2017) Brooke E. Howitt et al. OncoImmunology
- Anti-angiogenic agents in ovarian cancer: past, present, and future
- (2016) B. J. Monk et al. ANNALS OF ONCOLOGY
- Low-grade serous ovarian cancer: A review
- (2016) Anis Kaldawy et al. GYNECOLOGIC ONCOLOGY
- Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- (2016) Mikkel Rosendahl et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
- (2016) Mary B. Daly et al. Journal of the National Comprehensive Cancer Network
- Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
- (2016) Ian J Jacobs et al. LANCET
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of tissue-specific cell death using methylation patterns of circulating DNA
- (2016) Roni Lehmann-Werman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California
- (2015) Beverly Long et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Ovarian cancer treatment: The end of empiricism?
- (2015) Stephanie Lheureux et al. CANCER
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care
- (2015) Natalia Rodriguez Gómez-Hidalgo et al. GYNECOLOGIC ONCOLOGY
- Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions
- (2015) Johnathan M. Lancaster et al. GYNECOLOGIC ONCOLOGY
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication
- (2015) Jaime Prat Journal of Gynecologic Oncology
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
- (2015) Sean Kehoe et al. LANCET
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas
- (2015) Yuriko Uehara et al. PLoS One
- Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary
- (2014) Koah R. Vierkoetter et al. GYNECOLOGIC ONCOLOGY
- A mouse model for endometrioid ovarian cancer arising from the distal oviduct
- (2014) Paul H. van der Horst et al. INTERNATIONAL JOURNAL OF CANCER
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma
- (2014) Jonathan A. Ledermann et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer
- (2014) Gottfried E. Konecny et al. JNCI-Journal of the National Cancer Institute
- Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples
- (2014) Markus Riester et al. JNCI-Journal of the National Cancer Institute
- Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
- (2014) Sandro Pignata et al. LANCET ONCOLOGY
- Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
- (2013) R. J. Kurman ANNALS OF ONCOLOGY
- New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
- (2013) S. Banerjee et al. CLINICAL CANCER RESEARCH
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- Staging classification for cancer of the ovary, fallopian tube, and peritoneum
- (2013) Jaime Prat et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Eliminating Racial Disparities in Colorectal Cancer in the Real World: It Took a Village
- (2013) Stephen S. Grubbs et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
- (2013) Noriyuki Katsumata et al. LANCET ONCOLOGY
- Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles
- (2013) Melissa K McConechy et al. MODERN PATHOLOGY
- How to approach patients in relapse
- (2012) E. Pujade-Lauraine ANNALS OF ONCOLOGY
- New insights into ovarian cancer pathology
- (2012) J. Prat ANNALS OF ONCOLOGY
- The Ohio Patient Navigation Research Program: Does the American Cancer Society Patient Navigation Model Improve Time to Resolution in Patients with Abnormal Screening Tests?
- (2012) E. D. Paskett et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Patient Navigation Improves Cancer Diagnostic Resolution: An Individually Randomized Clinical Trial in an Underserved Population
- (2012) P. C. Raich et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Disparity in cancer care: a Canadian perspective
- (2012) S. Ahmed et al. Current Oncology
- Global ovarian cancer health disparities
- (2012) Ganna Chornokur et al. GYNECOLOGIC ONCOLOGY
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
- (2012) John Farley et al. LANCET ONCOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features
- (2012) Jaime Prat VIRCHOWS ARCHIV
- Low-grade serous carcinomas of the ovary contain very few point mutations
- (2011) Siân Jones et al. JOURNAL OF PATHOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data
- (2010) MP Coleman et al. LANCET
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer
- (2010) Dariush Etemadmoghadam et al. PLoS One
- Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing
- (2010) Tom Walsh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
- (2009) Andreas du Bois et al. CANCER
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
- (2009) Noriyuki Katsumata et al. LANCET
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
- (2008) R. W. Tothill et al. CLINICAL CANCER RESEARCH
- Contents of Endometriotic Cysts, Especially the High Concentration of Free Iron, Are a Possible Cause of Carcinogenesis in the Cysts through the Iron-Induced Persistent Oxidative Stress
- (2008) K. Yamaguchi et al. CLINICAL CANCER RESEARCH
- Folate receptor alpha as a tumor target in epithelial ovarian cancer
- (2008) Kimberly R. Kalli et al. GYNECOLOGIC ONCOLOGY
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
- (2008) Richard G. Moore et al. GYNECOLOGIC ONCOLOGY
- “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations
- (2008) David S.P. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- A Culturally Tailored Navigator Program for Colorectal Cancer Screening in a Community Health Center: A Randomized, Controlled Trial
- (2008) Sanja Percac-Lima et al. JOURNAL OF GENERAL INTERNAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started